Alzheimer Disease, Cognition Disorders
Conditions
Brief summary
This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer's Disease drug research trial.
Interventions
For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
Sponsors
Eli Lilly and Company
PRA Health Sciences
Avid Radiopharmaceuticals
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients ≥ 50 years of age at the time of consent; * Patients who have objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease; * Patients who are willing to make available to Avid a positive amyloid scan, or if an amyloid scan is not available, are willing to undergo amyloid scanning via the Florbetapir F 18 PET Scan Addendum; * Patients who are willing to be contacted for possible participation in Lilly drug research trials targeting Alzheimer's disease; * Patients who give informed consent or have a legally authorized representative (LAR) to consent for enrollment; and * Patients who have a partner (informant) who is willing to participate as a source of information and has at least weekly contact with the patient (contact can be inperson, via telephone or electronic communication). The informant must have sufficient contact such that the referring physician feels the informant can provide meaningful information about the patient.
Exclusion criteria
* Patients who have a Mini Mental State Examination (MMSE) score of \< 16; * Patients who have an amyloid-negative PET scan (either a historical scan or scan via the Florbetapir F 18 PET Scan Addendum); * Patients who have serious or unstable medical conditions that would exclude completion of all procedures and data collection for the registry, or would be likely to preclude participation in a drug research trial; * Patients who are currently participating in a clinical trial with an investigational agent; or * Patients who, in the opinion of the physician, are otherwise unsuitable for this registry.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Registry Participation | Two years | There is no formal hypothesis to test in this registry study. The registry will collect contact information of amyloid positive patients with cognitive impairment who have indicated interest in being contacted for a Lilly AD drug research trial. The primary outcome measure to be reported is the total number of participants in the registry. |
Countries
United States
Outcome results
None listed